Background illustration for clinical trials search

Paid Clinical Trials Worcester

Discover 3,097 paid clinical trials in Worcester, Massachusetts. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 3,097

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

for

Lung Non-Small Cell Carcinoma

Location: Worcester MA, Burlington MA, Springfield MA, Peabody MA,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06116682

Phase2, Recruiting

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

for

Acute Leukemia of Ambiguous Lineage,

Location: Worcester MA, Boston MA, Providence RI, New Haven CT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 0 - 1

Code: NCT06317662

Phase2, Recruiting

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

for

Carcinoma, Non-Small-Cell Lung

Location: Worcester MA, Hartford CT, Westbrook ME, New York NY,

Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT06890598

Phase3, Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

for

Non-Small Cell Lung Cancer (NSCLC)

Location: Worcester MA, Montreal, Sayre PA, Media PA, Newark DE,

Sponsor: Amgen

Sex: All

Age: 18 - 70+

Code: NCT05920356

Phase3, Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

for

Non-Small Cell Lung Cancer

Location: Worcester MA, Foxborough MA, Brighton MA, Boston MA,

Sponsor: Summit Therapeutics

Sex: All

Age: 18+

Code: NCT06767514

Phase3, Recruiting

Myasthenia Gravis Foundation of America Global MG Patient Registry

for

Myasthaenia Gravis, Myasthenia,

Location: Westborough MA

Sponsor: Myasthenia Gravis Foundation of America

Sex: All

Age: 18+

Code: NCT06617741

Recruiting

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for

Breast Cancer

Location: Milford MA, Newton MA, Foxborough MA, Boston MA,

Sponsor: Stemline Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06492616

Phase3, Recruiting

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

for

Monoclonal Gammopathy of Undetermined Significance (MGUS),

Location: Milford MA, Brighton MA, Boston MA, Methuen MA,

Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT02269592

Recruiting

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

for

Intermediate Risk Prostate Cancer, High Risk Prostate Cancer,

Location: Milford MA, Weymouth MA

Sponsor: Martin T. King, MD, PhD

Sex: Male

Age: 18+

Code: NCT07393867

Phase2, Recruiting

Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial

for

Glioblastoma (GBM)

Location: Milford MA, Boston MA, South Weymouth MA

Sponsor: Brigham and Women's Hospital

Sex: All

Age: 65+

Code: NCT06835803

Phase2, Recruiting

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

for

Castration-Resistant Prostate Carcinoma,

Location: Milford MA, Foxborough MA, Springfield MA, Methuen MA,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT06632977

Phase2, Recruiting

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

for

Breast Cancer, Triple Negative Breast Cancer, PD-L1 Negative

Location: Milford MA, Foxborough MA, Boston MA, South Weymouth MA,

Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT04468061

Phase2, Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for

Triple Negative Breast Cancer

Location: Milford MA, Foxborough MA, Boston MA, Providence RI,

Sponsor: Gilead Sciences

Sex: All

Age: 18+

Code: NCT05633654

Phase3, Recruiting

ATEMPT 2.0: Adjuvant T-DM1 vs TH

for

Breast Cancer, HER2-positive Breast Cancer

Location: Milford MA, Newton MA, Foxborough MA, Brighton MA,

Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT04893109

Phase2, Recruiting

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

for

Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8,

Location: Milford MA, Boston MA, South Weymouth MA, Sanford ME,

Sponsor: NRG Oncology

Sex: Male

Age: 18+

Code: NCT05946213

Phase3, Recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for

Muscle Invasive Bladder Urothelial Carcinoma,

Location: Milford MA, Foxborough MA, Brighton MA, Burlington MA,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05987241

Phase2, Phase3, Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

for

Advanced Non-Small Cell Lung Cancer,

Location: Milford MA, Foxborough MA, Brighton MA, Boston MA,

Sponsor: Mirati Therapeutics Inc.

Sex: All

Age: 18+

Code: NCT04613596

Phase2, Phase3, Recruiting

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

for

Advanced Lung Non-Small Cell Carcinoma,

Location: Milford MA, Foxborough MA, Brighton MA, Boston MA,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 70+

Code: NCT06096844

Phase3, Recruiting

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

for

Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC),

Location: Milford MA, Foxborough MA, Burlington MA, Boston MA,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT06661720

Phase3, Recruiting

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

for

Plaque Psoriasis

Location: Milford MA, Boston MA, Cromwell CT, New York NY,

Sponsor: Oruka Therapeutics, Inc.

Sex: All

Age: 18 - 70+

Code: NCT07474792

Phase2, Recruiting

Paid Clinical Trials Worcester

Filter results

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Interested in new trials?

Myasthenia Gravis Foundation of America Global MG Patient Registry

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

ATEMPT 2.0: Adjuvant T-DM1 vs TH

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis